CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for...
Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA
CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for metastatic urothelial carcinoma ( Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA )
13 Jun 2019
Maintenance pembrolizumab vs placebo for metastatic urothelial cancer
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
Maintenance pembrolizumab vs placebo for metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )
13 Jun 2019
NILE: Should we give everything to patients with unresectable locally advanced o...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
NILE: Should we give everything to patients with unresectable locally advanced or metastatic urothelial cancer? ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )
13 Jun 2019
SWOG 1314: A study of co-expression extrapolation (COXEN) with neoadjuvant chemo...
Prof Thomas Flaig - University of Colorado Denver, Denver, USA
SWOG 1314: A study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for muscle-invasive bladder cancer ( Prof Thomas Flaig - University of Colorado Denver, Denver, USA )
10 Jun 2019
Genetic testing and PARP inhibitors in metastatic prostate cancer
Dr Neal Shore and Dr Joaquin Mateo
Genetic testing and PARP inhibitors in metastatic prostate cancer ( Dr Neal Shore and Dr Joaquin Mateo )
7 Jun 2019
Metastatic castration resistant prostate cancer: Updates from ASCO 2019
Dr Neal Shore, Dr Joaquin Mateo and Prof Karim Fizazi
Metastatic castration resistant prostate cancer: Updates from ASCO 2019 ( Dr Neal Shore, Dr Joaquin Mateo and Prof Karim Fizazi )
7 Jun 2019
Prostate cancer updates: TITAN and ENZAMET
Prof Ian Davis and Prof Axel Merseburger
Prostate cancer updates: TITAN and ENZAMET ( Prof Ian Davis and Prof Axel Merseburger )
3 Jun 2019
Clinical updates for metastatic hormone sensitive prostate cancer at ASCO 2019
Prof Rob Jones, Prof Nick James, Prof Ian Davis, Prof Axel Merseburger
Clinical updates for metastatic hormone sensitive prostate cancer at ASCO 2019 ( Prof Rob Jones, Prof Nick James, Prof Ian Davis, Prof Axel Merseburger )
3 Jun 2019
Metastatic bladder cancer: Current practice and latest data from ASCO 2019
Dr Andrea Necchi, Dr Petros Grivas, Prof Arlene Siefker-Radtke, Prof Rob Jones
Metastatic bladder cancer: Current practice and latest data from ASCO 2019 ( Dr Andrea Necchi, Dr Petros Grivas, Prof Arlene Siefker-Radtke, Prof Rob Jones )
3 Jun 2019
Highlights from ASCO 2019
Asst. Prof Bishal Gyawali and Monique Biryiana
Highlights from ASCO 2019 ( Asst. Prof Bishal Gyawali and Monique Biryiana )
3 Jun 2019
Targeting agent enfortumab vedotin a novel treatment for patients with advanced ...
Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA
Targeting agent enfortumab vedotin a novel treatment for patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )
3 Jun 2019
New agent targeting Nectin-4 produces responses in nearly half of patients with ...
Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA
New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )
3 Jun 2019